Literature DB >> 20214912

Characterization of active and inactive states of CB1 receptor and the differential binding state modulation by cannabinoid agonists, antagonists and inverse agonists.

Srinivas Gullapalli1, Dipak Amrutkar, Sangeetha Gupta, Machender R Kandadi, Hemant Kumar, Maulik Gandhi, Vikas Karande, Shridhar Narayanan.   

Abstract

Cannabinoid 1 (CB1) receptors have the ability to change conformation between active (R*) and inactive (R) receptor states. Herein, we further characterize these receptor states using series of saturation radioligand binding studies and their differential displacement binding by various CB1 receptor ligands. Binding experiments were carried out in naïve rat/dog whole brain membranes using radioligands [(3)H]CP55,940 (for R* state) & [(3)H]SR141716A (both R* and R states) and various agonist, antagonist & inverse agonist ligands at CB1 receptors. In the saturation binding experiments, of the total number of CB1 receptor binding sites (R* + R) in the rat and dog whole brain membranes, only about 18.3 and 11.6% were in the active (R*) state recognized by [(3)H]CP55,940, respectively. In the competitive binding studies, all the CB1 receptor agonists investigated had significantly very high affinity for the active R* state recognized by [(3)H]CP55,940 and lower affinity for the inactive R state mainly recognized by [(3)H]SR141716A in the presence of a non-hydrolyzable analogue of GTP [Gpp(NH)p]. In contrast, various CB1 receptor antagonists/inverse agonists had similar nanomolar affinities at both [(3)H]CP55,940 and [(3)H]SR141716A recognized binding states. These results clearly characterize the significant differences between the active R* and inactive R binding states of CB1 receptors in naive rat and dog brain. In addition, these results also demonstrates that the CB1 agonists and antagonists/inverse agonists can be differentiated by their relative affinities at active (R*) and inactive (R) binding states of the CB1 receptor. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20214912     DOI: 10.1016/j.neuropharm.2010.03.001

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

1.  Preclinical evaluation of [18 F]MA3: a CB2 receptor agonist radiotracer for PET.

Authors:  Bala Attili; Sofie Celen; Muneer Ahamed; Michel Koole; Chris Van Den Haute; Wim Vanduffel; Guy Bormans
Journal:  Br J Pharmacol       Date:  2019-01-30       Impact factor: 8.739

2.  3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.

Authors:  Jenny L Wiley; Dana E Selley; Pinglang Wang; Rudresha Kottani; Srinivas Gadthula; Anu Mahadeven
Journal:  J Pharmacol Exp Ther       Date:  2011-11-15       Impact factor: 4.030

3.  Brain imaging of cannabinoid type I (CB1 ) receptors in women with cannabis use disorder and male and female healthy controls.

Authors:  Tory R Spindle; Hiroto Kuwabara; Alisha Eversole; Ayon Nandi; Ryan Vandrey; Denis G Antoine; Annie Umbricht; Angela S Guarda; Dean F Wong; Elise M Weerts
Journal:  Addict Biol       Date:  2021-05-24       Impact factor: 4.093

Review 4.  Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?

Authors:  Matthieu Colom; Benjamin Vidal; Luc Zimmer
Journal:  Front Mol Neurosci       Date:  2019-10-18       Impact factor: 5.639

5.  Design and validation of recombinant protein standards for quantitative Western blot analysis of cannabinoid CB1 receptor density in cell membranes: an alternative to radioligand binding methods.

Authors:  Miquel Saumell-Esnaola; Ainhoa Elejaga-Jimeno; Leyre Echeazarra; Leire Borrega-Román; Sergio Barrondo; Maider López de Jesús; Imanol González-Burguera; Alberto Gómez-Caballero; María Aranzazu Goicolea; Joan Sallés; Gontzal García Del Caño
Journal:  Microb Cell Fact       Date:  2022-09-15       Impact factor: 6.352

6.  Cannabinoid receptor type 2 (CB2)-selective N-aryl-oxadiazolyl-propionamides: synthesis, radiolabelling, molecular modelling and biological evaluation.

Authors:  Thomas Rühl; Winnie Deuther-Conrad; Steffen Fischer; Robert Günther; Lothar Hennig; Harald Krautscheid; Peter Brust
Journal:  Org Med Chem Lett       Date:  2012-10-15

7.  Synthesis, Biodistribution and In vitro Evaluation of Brain Permeable High Affinity Type 2 Cannabinoid Receptor Agonists [11C]MA2 and [18F]MA3.

Authors:  Muneer Ahamed; Daisy van Veghel; Christoph Ullmer; Koen Van Laere; Alfons Verbruggen; Guy M Bormans
Journal:  Front Neurosci       Date:  2016-09-22       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.